Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice (EVOLUTION-HF)

March 25, 2025 updated by: AstraZeneca

Early Treatment of Heart Failure: a Non-Interventional Observational Study of Italian Patients With Heart Failure and Initiated on Dapagliflozin

This is an observational, non-interventional, longitudinal prospective descriptive study including participants diagnosed with Heart Failure with reduced Ejection Fraction (HFrEF) in Italy and initiated on treatment with dapagliflozin according to the approved HFrEF indication. The study is aimed at providing insights into real-world drug utilization and treatment patterns of dapagliflozin in the Italian HFrEF setting, as well as patient-reported outcomes including quality of life.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Heart failure (HF) is a significant burden for public health, affecting more than 63 million people worldwide and expected to increase as the population ages; in Italy, the estimated prevalence of HF is 1-3% and the incidence rate 2-5 cases per 1000 persons per year. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality and impacts on patients' quality of life (QoL). Dapagliflozin is the first in a novel class of glucose-lowering agents known as sodium-glucose co-transporter-2 (SGLT2) inhibitors, approved for the treatment of Heart Failure with reduced Ejection Fraction (HFrEF). As with all new drugs introduced into clinical practice, there is a strong scientific interest in producing evidence from observational studies regarding the use of dapagliflozin for the treatment of HFrEF in real-world settings with detailed clinical data on heart failure symptoms, outcomes, and health-related QoL.

The overall aim of this observational study is to describe the characteristics of patients in Italy initiating dapagliflozin for the treatment of HFrEF and to provide early insights into real-world dapagliflozin treatment patterns (primary objectives) as well as patient-reported outcomes including quality of life (secondary objectives).

This study is part of a multicountry study programme, including similar studies that will be conducted in other countries with similar objectives. Data from each of the individual studies may be combined in a pooled analysis.

Study Type

Observational

Enrollment (Actual)

252

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Napoli, Italy, 80131
        • Research Site
    • BS
      • Brescia, BS, Italy, 25123
        • Research Site
    • CZ
      • Catanzaro, CZ, Italy, 88100
        • Research Site
    • FG
      • Foggia, FG, Italy, 71122
        • Research Site
    • FI
      • Firenze, FI, Italy, 50100
        • Research Site
    • GE
      • Genova, GE, Italy, 16132
        • Research Site
    • MB
      • Monza, MB, Italy, 20900
        • Research Site
    • MI
      • Milano, MI, Italy, 20122
        • Research Site
    • RM
      • Roma, RM, Italy, 00163
        • Research Site
      • Roma, RM, Italy, 00189
        • Research Site
    • TS
      • Trieste, TS, Italy, 34125
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients prescribed with dapagliflozin for Heart Failure with reduced Ejection Fraction (HFrEF) according to the approved indication will be eligible for enrollment from both outpatient and inpatient settings.

The decision to treat a patient with dapagliflozin must be made prior to the decision to enroll the patient. In order to help ensuring this, participants can be enrolled only if they started treatment with dapagliflozin at least 14 days before the enrollment visit, regardless of the treatment being discontinued or suspended in the time between first dapagliflozin prescription and enrollment visit.

It is expected that 250 participants will be consecutively enrolled in about 11 centres (approximately 23 participants per each study site).

Description

Inclusion Criteria:

  • Age equal or above 18 years old at the initiation of treatment with dapagliflozin
  • Participant received/receiving treatment with dapagliflozin for Heart Failure with reduced Ejection Fraction (HFrEF) in accordance with the approved local dapagliflozin product label, i.e. with an ejection fraction of 40 percent or less
  • Signed and dated informed cconsent obtained prior to enrollment into the study

Exclusion Criteria:

  • Participant is enrolled less than 14 days or more than 45 days following the initiation of treatment with dapagliflozin
  • Prior treatment with dapagliflozin or other treatment with a medicine of the same drug class (sodium-glucose co-transporter-2 - or SGLT2 - inhibitors)
  • Initiation of dapagliflozin outside of the approved local dapagliflozin product label for HFrEF
  • Diagnosis of Type 1 Diabetes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Single-cohort
Patients initiated on dapagliflozin according to the approved indication for heart failure with reduced ejection fraction (HFrEF) and current medical practice
Dapagliflozin, prescribed as per approved indication and current medical practice. Participants will not receive any experimental disease management intervention or experimental treatment as a consequence of their participation in the study.
Other Names:
  • Forxiga

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Baseline characteristics of participants
Time Frame: Baseline (enrollment)
Demographic and clinical characteristics at baseline of study participants
Baseline (enrollment)
Dapagliflozin treatment pattern
Time Frame: 12 months from prescription of dapagliflozin
Treatment discontinuation events for dapagliflozin
12 months from prescription of dapagliflozin
Other medications treatment patterns
Time Frame: 12 months from prescription of dapagliflozin
Treatment change events for other medications for heart failure and glucose-lowering medications
12 months from prescription of dapagliflozin

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Reported Outcome: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time Frame: Baseline (enrollment), Follow-up (3, 6, 12 months after treatment initiation)
Health-Related Quality of Life: assessment of heart failure symptoms and their impact in terms of physical limitation and quality of life, as captured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ is scored on a scale from 0 to 100, with higher scores indicating higher quality of life.
Baseline (enrollment), Follow-up (3, 6, 12 months after treatment initiation)
Patient Reported Outcome: Medication Adherence Report Scale (MARS-5)
Time Frame: Baseline (enrollment), Follow-up (3, 6, 12 months after treatment initiation)
Assessment of medication adherence to heart failure treatments, as captured by the five-items version of the Medication Adherence Report Scale (MARS-5). The MARS-5 is scored on a scale from 0 to 25, with higher scores indicating better treatment compliance.
Baseline (enrollment), Follow-up (3, 6, 12 months after treatment initiation)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Marco Metra, MD, UOC Cardiologia, Spedali Civili di Brescia
  • Principal Investigator: Maurizio Volterrani, MD, UO Riabilitazione Cardiologica, IRCCS San Raffaele, Roma
  • Principal Investigator: Pasquale Perrone Filardi, MD, UOC Cardiologia emodinamica e UTIC, Azienda Ospedaliera Universitaria "Federico II", Napoli
  • Principal Investigator: Massimo Iacoviello, MD, Unità di Cardiologia, Azienda Ospedaliero Universitaria Ospedali Riuniti, Foggia
  • Principal Investigator: Pietro Ameri, MD, UO Clinica Malattie Apparato Cardiovascolare e UTIC, IRCCS Ospedale Policlinico San Martino, Genova
  • Principal Investigator: Andrea Ungar, MD, Geriatria UTIG, Azienda Ospedaliero Universitaria Careggi, Firenze
  • Principal Investigator: Ciro Indolfi, MD, UO Cardiologia-Emodinamica-UTIC, Azienda Ospedaliero Universitaria Mater Domini, Catanzaro
  • Principal Investigator: Massimo Volpe, MD, UOC Cardiologia, Azienda Ospedaliera Sant'Andrea, Roma
  • Principal Investigator: Andrea Mortara, MD, Dipartimento di Cardiologia, Policlinico di Monza, Monza
  • Principal Investigator: Stefano Carugo, MD, Unità di Cardiologia, IRCCS Ca' Granda - Ospedale Maggiore - Policlinico, Milano
  • Principal Investigator: Andrea Di Lenarda, MD, Cardiologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 19, 2022

Primary Completion (Actual)

April 15, 2024

Study Completion (Actual)

April 15, 2024

Study Registration Dates

First Submitted

January 20, 2022

First Submitted That Met QC Criteria

February 10, 2022

First Posted (Actual)

February 22, 2022

Study Record Updates

Last Update Posted (Actual)

March 28, 2025

Last Update Submitted That Met QC Criteria

March 25, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • D1699R00030

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca sponsored studies via the request portal.

All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. AZ are accepting requests for IPD, but this does not mean all requests will be shared.

IPD Sharing Time Frame

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

IPD Sharing Access Criteria

When a request has been approved, AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.